This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clini ...
Over-colonization and subsequent inflammation triggered by Cutibacterium acnes is the primary factor in the pathogenesis of acne vulgaris, a prevalent skin condition among adolescents. Gyeongsang ...